No Stock Yet
RBC Capital : initiated coverage of Haleon (HLN) with a Sector Perform rating and 300 GBp price target.
Haleon Target Started at 300p by RBC
Haleon PLC - Statement re Zantac
WEYBRIDGE, UK / ACCESSWIRE / August 11, 2022 / Haleon plc (LSE:HLN) notes the recent volatility in its share price and is aware of market speculation on Haleon's potential liability in respect of Zant
Haleon Brands Lack Market Leading Positions, RBC Says -- Market Talk
0939 GMT - Haleon is currently lacking a competitive edge, RBC Capital Markets analysts James Edwardes Jones and Emma Letheren say in a research note. Given a shortage of market leading positions in i
Li Auto, Haleon, Sibanye Stillwater Among Premarket Losers' Pack
Turquoise Hill Resources (TRQ) -18% after Turquoise Hill rejects Rio Tinto's bid to take control of huge Mongolia mine. Arcadia Biosciences (RKDA) -18% to raise $5M in securities offering. Root (ROOT)
Li Auto And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
Turquoise Hill Resources Ltd. (NYSE:TRQ) shares fell 18.1% to $21.50 in pre-market trading after the company's special committee rejected Rio Tinto's offer worth $2.7 billion for the rest 49% stake in
Changes in US stocks | Sanofi, Haleon and GlaxoSmithKline PLC were all frustrated by the Zantac lawsuit.
On August 15, Gelonghui, Sanofi, Haleon and GlaxoSmithKline PLC fell 1.92%, 5.7% and 3.03% respectively before trading. GlaxoSmithKline PLC and Sanofi defended their position at Zantac in a statement on Thursday to reassure investors about the high-profile lawsuit over the recall of heartburn drug Zantac, pointing out that since 2019, studies conducted by different institutions and companies have shown no evidence that ranitidine causes cancer. In 2019, Zantac due to "unacceptable levels of N-nitrosodimethylamine"
Potential Zantac Litigation Costs Are Still Impossible to Estimate -- Market Talk
1631 GMT - The market has priced in a potential legal settlement of more than $40 billion over allegedly carcinogenic effects of Zantac, a drug manufactured by various companies through the years, inc
Xiao Mo: the market overreacted to the Zantac lawsuit and strongly supported GlaxoSmithKline PLC and Sanofi.
Analysts at the bank believe that the market capitalization of these companies has been hit "more than the worst-case scenario" this week, and that the market has not fairly considered any potential liability of Zantac among the companies concerned.
Sanofi may not be liable for any Zantac litigation damages, says JPMorgan
JPMorgan analysts Richard Vosser and James Gordon note that shares of GSK plc (GSK), Sanofi (SNY), Haleon (HLN) and Pfizer (PFE) have lost a combined market cap of $44B week to date, which they attrib
Zantac lawsuit tumbled share prices GlaxoSmithKline PLC (GSK.US) and SNY.US (Sanofi) issued announcements to reassure investors
Zhitong Financial APP learned that recently, there has been an uproar over the recall of heartburn drug Zantac (ranitidine), which has greatly wiped out the market value of a number of pharmaceutical companies involved. To reassure investors, GlaxoSmithKline PLC and SNY.US issued statements on Thursday defending their positions at Zantac, pointing out that since 2019, studies conducted by different institutions and companies have shown that there is no evidence that ranitidine causes cancer. As of press time, GlaxoSmithKline PLC was down 0.22% before trading, while Sanofi was up 1.73%. It is understood that Ben
No Stock Yet